Will Downsized Korean Biopharma Investment Fund Launch Successfully This Time?
Weak But Improving Sentiment
Given that previously announced similar programs failed to attract strong investor interest, South Korea is set to create a new biopharma fund but of a smaller target size and lower qualifying thresholds as it continues to support industry development.
You may also be interested in...
South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.
South Korean firm AriBio is planning to expand global Phase III trials for its oral Alzheimer’s disease candidate following an IND approval at home. Patient enrolment in a US trial began late last year.
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.